TY - JOUR
T1 - Delayed first injection of the once-a-month injectable contraceptive containing 25 mg of medroxyprogesterone acetate and 5 mg of E2-cypionate
T2 - Effects on ovarian function
AU - Petta, Carlos Alberto
AU - Hays, Melissa
AU - Brache, Vivian
AU - Massai, Rebeca
AU - Hua, Yang
AU - Alvarez-Sánchez, Francisco
AU - Croxatto, Horacio
AU - D'Arcangues, Catherine
AU - Cook, Lynley A.
AU - Bahamondes, Luis
N1 - Funding Information:
Support for this work was provided with funds from the United States Agency for International Development (USAID) cooperative agreement AID/CCP-3079-A-00-5022-00 and the UNDP/UNFPA/WHO/World Bank Special Program of Research Development and Research Training in Human Reproduction for the China site. The views expressed in this document, however, do not necessarily reflect those of the funding agencies.
PY - 2001
Y1 - 2001
N2 - Objective: To assess whether women who were administered the first injection of DMPA+E2C on day 7 of their menstrual cycle (delayed injection) exhibit the same degree of ovarian suppression as women who receive it on day 5 of their menstrual cycle. Design: Multicenter, randomized controlled trial.Setting: Reproductive health clinics. Patient(s): Women aged between 18 and 38 years (inclusive) willing to use DMPA+E2C as their method of contraception. Intervention(s): Participants received a DMPA+E2C injection on day 5 (control group, n = 41) or day 7 (delayed-injection group, n = 117) of their menstrual cycle. Main Outcome Measure(s): Ovarian activity and follicular development determined by serial serum progesterone levels and vaginal ultrasound. Result(s): Participants who received DMPA+E2C on day 5 of their menstrual cycle (control group) exhibited no more than limited follicular growth (no follicle >16 mm). Of those women who received DMPA+E2C on day 7 of their menstrual cycle (delayed-injection group), 21 (18%) showed some follicular growth, of whom 4 (3%) ovulated. Conclusion(s): The first injection of DMPA+E2C given on day 7 of a menstrual cycle does not provide the same inhibition of ovarian activity as that observed when it is administered on day 5 of the menstrual cycle.
AB - Objective: To assess whether women who were administered the first injection of DMPA+E2C on day 7 of their menstrual cycle (delayed injection) exhibit the same degree of ovarian suppression as women who receive it on day 5 of their menstrual cycle. Design: Multicenter, randomized controlled trial.Setting: Reproductive health clinics. Patient(s): Women aged between 18 and 38 years (inclusive) willing to use DMPA+E2C as their method of contraception. Intervention(s): Participants received a DMPA+E2C injection on day 5 (control group, n = 41) or day 7 (delayed-injection group, n = 117) of their menstrual cycle. Main Outcome Measure(s): Ovarian activity and follicular development determined by serial serum progesterone levels and vaginal ultrasound. Result(s): Participants who received DMPA+E2C on day 5 of their menstrual cycle (control group) exhibited no more than limited follicular growth (no follicle >16 mm). Of those women who received DMPA+E2C on day 7 of their menstrual cycle (delayed-injection group), 21 (18%) showed some follicular growth, of whom 4 (3%) ovulated. Conclusion(s): The first injection of DMPA+E2C given on day 7 of a menstrual cycle does not provide the same inhibition of ovarian activity as that observed when it is administered on day 5 of the menstrual cycle.
KW - Contraception
KW - Cyclofem
KW - Ovulation
KW - Progesterone
KW - Randomized controlled trial
KW - Ultrasound
UR - http://www.scopus.com/inward/record.url?scp=0035075506&partnerID=8YFLogxK
U2 - 10.1016/S0015-0282(01)01672-7
DO - 10.1016/S0015-0282(01)01672-7
M3 - Article
C2 - 11287029
AN - SCOPUS:0035075506
SN - 0015-0282
VL - 75
SP - 744
EP - 748
JO - Fertility and Sterility
JF - Fertility and Sterility
IS - 4
ER -